Evidence map›Paper›PMID 35883450›Full record

ReviewBiomolecules2022

Pitfalls of Antiretroviral Therapy: Current Status and Long-Term CNS Toxicity.

Harrison Rudd, Michal Toborek

Open access · goldAbstract readReview
In one paragraph

Review in Biomolecules, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
1.0field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 14 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Review
  6. Article
  7. Neurological complications caused by SARS-CoV-2.Clinical microbiology reviews · 2024
    Review
  8. Article
  9. Article
  10. Article
  11. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 1 institution in 2 countries.

Harrison RuddDepartment of Biochemistry and Molecular Biology, University of Miami Miller School of Medicine, Miami, FL 33136, USA.ORCID 0000-0001-6637-2251
Michal ToborekDepartment of Biochemistry and Molecular Biology, University of Miami Miller School of Medicine, Miami, FL 33136, USA.ORCID 0000-0003-4475-2119
University of Miami · US

Funding

Defining brain pericytes as a novel and myeloid-derived HIV reservoirR01MH128022 · NIMH · UNIVERSITY OF MIAMI SCHOOL OF MEDICINE · PI TOBOREK, MICHAL · 2021 to 2025
$2.3M
Prevention of HIV and drug abuse-induced brain pathology by targeting mitochondriaR01DA044579 · NIDA · UNIVERSITY OF MIAMI SCHOOL OF MEDICINE · PI TOBOREK, MICHAL · 2017 to 2021
$2.2M
National Heart Lung and Blood Institute HL126559NIDA NIH HHS DA044579, DA039576, DA040537, DA050528, DA047157NIMH NIH HHS MH128022, MH122235, MH072567, MH12223
6 · The paper itself

Abstract

HIV can traverse the BBB using a Trojan horse-like mechanism. Hidden within infected immune cells, HIV can infiltrate the highly safeguarded CNS and propagate disease. Once integrated within the host genome, HIV becomes a stable provirus, which can remain dormant, evade detection by the immune system or antiretroviral therapy (ART), and result in rebound viraemia. As ART targets actively replicating HIV, has low BBB penetrance, and exposes patients to long-term toxicity, further investigation into novel therapeutic approaches is required. Viral proteins can be produced by latent HIV, which may play a synergistic role alongside ART in promoting neuroinflammatory pathophysiology. It is believed that the ability to specifically target these proviral reservoirs would be a vital driving force towards a cure for HIV infection. A novel drug design platform, using the in-tandem administration of several therapeutic approaches, can be used to precisely target the various components of HIV infection, ultimately leading to the eradication of active and latent HIV and a functional cure for HIV. The aim of this review is to explore the pitfalls of ART and potential novel therapeutic alternatives.

Indexed as

HIV-1HIV InfectionsHumansVirus Latencyantiretroviral therapyblood-brain barrierbrainHIVneuroHIV

Identifiers

PMID35883450
PMCPMC9312798
OpenAlexW4283513359

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.